ACCESS Newswire

Moderna, Inc.

15.9.2023 08:37:29 CEST | ACCESS Newswire | Press release

Share
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s Updated Covid-19 Vaccine in The European Union

The positive opinion follows the recommendation from regulators and global public health bodies to develop monovalent XBB.1.5 COVID-19 vaccines for autumn/winter 2023 vaccination campaigns

Clinical trial data from research assay confirmed Moderna's updated COVID-19 vaccine showed an 8.7 to 11-fold increase in neutralizing antibodies against circulating variants, including BA.2.86, EG.5, and FL.1.5.1 variants

CAMBRIDGE, MA / ACCESSWIRE / September 14, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for Spikevax, its updated COVID-19 vaccine containing spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. Following the CHMP's positive opinion, the European Commission will make an authorization decision on the use of Moderna's updated COVID-19 vaccine for autumn/winter 2023.

"The CHMP's positive recommendation for our updated COVID-19 vaccine is a key milestone given we see increasing transmission of SARS-CoV-2 across Europe. Our updated COVID-19 vaccine generates a strong human immune response against circulating variants, including BA.2.86, EG.5, and FL.1.5.1, and will be a critical tool for protection," said Stéphane Bancel, Chief Executive Officer of Moderna. "We are working with governments across Europe to include our updated COVID-19 vaccine in national vaccination programs, to ensure a diversified portfolio that provides vaccine choice and access to single dose vial formats, which can limit waste."

Moderna has generated clinical data of its monovalent XBB.1.5 vaccine candidate showing an immune response against XBB sublineages XBB.1.5, XBB.1.16, and XBB.2.3.2, in addition to BA.2.86, EG.5 and FL.1.5.1 variants. Public health authorities are vigilantly monitoring the BA.2.86 variant, a highly mutated strain of COVID-19 with over 30 mutations as compared to prior Omicron strains, with some governments accelerating COVID-19 vaccination campaigns due to its potential to break through protective immunity generated from previous COVID-19 vaccination or infection.

The most common solicited local adverse event for Moderna's updated COVID-19 vaccine was injection site pain. The most common solicited systemic adverse events include fatigue, headache, myalgia, arthralgia, and chills. Moderna's updated COVID-19 vaccine's safety profile is consistent with previous Spikevax formulations.

Moderna has received authorizations for its updated COVID-19 vaccine in the U.S., Canada, Japan, and Taiwan to date and has submitted regulatory applications worldwide.

About Moderna

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio and integrated manufacturing facilities that allow for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past eight years. To learn more, visit www.modernatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the potential authorization by the European Commission of Moderna's updated COVID-19 vaccine for autumn/winter 2023; the expectation that the European Commission's authorization decision will come shortly; the ability of Moderna's updated COVID-19 vaccine to induce an immune response against circulating variants of interest and provide protection for autumn/winter 2023; the safety profile of Moderna's updated COVID-19 vaccine; and Moderna's regulatory application submissions worldwide for its updated COVID-19 vaccine. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.

Moderna Contacts

Media:

Luke Mircea-Willats
Senior Director, International Communications
Luke.mirceawillats@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.



View source version on accesswire.com:
https://www.accesswire.com/784078/ema-committee-for-medicinal-products-for-human-use-adopts-positive-opinion-recommending-authorization-of-modernas-updated-covid-19-vaccine-in-the-european-union

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

APEX FTE Expo 2026 Unites Aviation Leaders in Singapore and Honors Passenger Experience Excellence20.11.2026 19:22:00 CET | Press release

SINGAPORE, SG / ACCESS Newswire / November 20, 2026 / APEX FTE EXPO 2026 brought together nearly 2,000 registered airline, airport, and industry leaders at Marina Bay Sands Expo & Convention Centre, bringing APEX's flagship show back to Singapore for the first time in a decade as the largest end-to-end passenger experience and innovation expo, spanning every stage of the passenger journey. Hosted by the Airline Passenger Experience Association (APEX), Future Travel Experience (FTE), and the International Flight Services Association (IFSA), the EXPO united over 300 airline representatives from more than 60 airlines worldwide, airport operators, and more than 100 exhibitors under one roof, building on 15 years of APEX FTE's Asia event. The two days culminated in the APEX Awards Ceremony, where the industry honored the leaders, airlines, and innovators whose work passengers feel long after they land. Across two days of airline chief executive keynotes, exclusive announcements, live culina

Tosca's 2026 Sustainability Report Makes the Case for Packaging as Critical Supply Chain Infrastructure20.11.2026 08:00:00 CET | Press release

BRUSSELS, BE / ACCESS Newswire / November 20, 2026 / Tosca, a global leader in reusable packaging and pooling solutions, has released its 2026 Sustainability Report, calling for a shift in how businesses evaluate transport packaging: from a purchased commodity to a strategic component of supply chain infrastructure. As food supply chains become more automated and face mounting cost and regulatory pressures, packaging decisions increasingly influence operational performance. The report examines how reusable packaging can reduce food loss, labor requirements and transportation inefficiencies while documenting Tosca's progress toward its global sustainability goals. "Companies invest significant resources in optimizing equipment, labor and transportation, yet packaging is still too often evaluated primarily on unit price," said Eric Frank, CEO of Tosca. "That approach overlooks its role in keeping automated lines running, protecting products and moving goods efficiently. Packaging is an o

Global Scams Remain Widespread: Nearly Two in Three Adults Worldwide Report Scam Encounters, 9% Lost Money19.11.2026 18:01:00 CET | Press release

THE HAGUE, NL / ACCESS Newswire / November 19, 2026 / The Global Anti-Scam Alliance (GASA), in collaboration with Outseer, today released the Global State of Scams 2026 report. Based on a survey of 58,900 adults across 42 markets, the report examines how often people encounter scams, how they respond, and the financial and emotional impact on those affected. In the past 12 months, 64% of adults worldwide encountered a scam and 9% lost money. Shopping, investment, and unexpected money scams were among the types people most often interacted with. In Africa, 21% of adults lost money to a scam, more than double the global rate. The research also highlights the emotional toll of scams. Among people who lost money, 69% reported a significant or moderate impact on their mental wellbeing, 20% reported increased tension at home, and 16% said they could not pay for essentials such as rent or groceries. Among those who did not report the scam to an organization, the most common reason was uncerta

After 20 Years of Modernizing Other Companies' Software, Polcode Turns the Lens on Itself19.11.2026 15:00:00 CET | Press release

WARSAW, PL / ACCESS Newswire / November 19, 2026 / Polcode, a software development company that has helped businesses across North America and Europe modernize their technology since 2006, launched its new website at polcode.com this week. Timed to the company's 20th anniversary, the launch is more than a redesign. It applies the same modernization approach Polcode brings to client systems every day to its own brand. For 20 years, Polcode has been the team businesses call when software stops keeping up with the business: aging platforms, tangled integrations, and tools nobody dares touch. So when it came time to rebuild its own website, the question was fair. Would a company that modernizes for others hold itself to the same standard? The new site is Polcode's answer, serving as both a showcase of what the company does and an example of it. We spend a lot of time helping businesses move beyond systems that no longer reflect where they're headed. At some point, we had to ask ourselves t

Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval19.11.2026 13:45:00 CET | Press release

CALGARY, AB / ACCESS Newswire / November 19, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a global carbon and environmental markets company, today announced that it has completed registration under the Compliance Instrument Tracking System Service (CITSS), enabling the Company to participate directly in California's regulated compliance carbon market. This milestone elevates Karbon-X's North American trading infrastructure, enabling the Company to directly source, hold, and transact compliance allowances and eligible offset credits, positioning the Company to capture trading margins and recurring commercial opportunities from California's ongoing compliance demand. Unlike voluntary carbon markets, California's Cap-and-Invest Program is backed by state regulation requiring covered entities to surrender eligible compliance instruments against their emissions obligations, creating recurring regulatory demand for allowances and eligible offset credits. California's pro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye